GSK’s Shares Surge After £1.68bn Heartburn Drug Settlement
Shares of the pharmaceutical giant GSK experienced a significant increase following a landmark settlement of £1.68 billion to resolve thousands of lawsuits in the US related to its discontinued heartburn drug Zantac. The company announced that it had reached an agreement with approximately 80,000 individuals who had filed lawsuits in the US, which accounts for around 93% of all claimants. These individuals had alleged that the drug caused cancer.
This settlement is viewed as a major success for GSK, especially since some analysts had predicted a much higher figure. JP Morgan, for example, had forecasted a settlement amount of £2.68 billion, significantly higher than the final agreement. The long-running issue surrounding Zantac, also known as ranitidine, has been a key focus for the company.
Zantac was a popular product in the treatment of indigestion, heartburn, and acid reflux, achieving blockbuster status by generating over a billion dollars in revenue. However, in 2019, concerns arose when a laboratory in Connecticut reported elevated levels of NDMA, a potentially harmful substance, in the drug when heated. Consequently, the drug was withdrawn as a precautionary measure in the UK and the US the following year.
Other pharmaceutical companies like Pfizer and Sanofi had already settled similar lawsuits related to their products. In response to the situation, GSK referred to subsequent research by regulatory agencies in the US and Europe that did not establish a definitive link between the drug and cancer. Notably, GSK did not acknowledge any liability in the settlements.
GSK indicated that it would fund the settlements using its existing financial resources, reassuring investors that the settlements would not impact the company’s growth plans or research and development initiatives. The positive news led to a 6% increase in GSK’s share price, with investors welcoming the lower-than-expected settlement amount.
Commenting on the development, Derren Nathan, head of equity research at Hargreaves Lansdown, described the settlement as a significant step towards concluding the prolonged legal battle. He noted that the outcome was better than anticipated and highlighted that the settlements reduce the investment risk associated with GSK shares, which are trading at a considerable discount compared to the sector.